{"id":1625,"date":"2016-12-06T12:29:37","date_gmt":"2016-12-06T12:29:37","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1625"},"modified":"2021-07-24T12:56:35","modified_gmt":"2021-07-24T07:26:35","slug":"notizia-17","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-17","title":{"rendered":"Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims to beat"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0e2a5260b58\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0e2a5260b58\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-17\/#Glaxo_replaces_ViiV_Healthcare_chief_as_executive_shuffle_continues\" >Glaxo replaces ViiV Healthcare chief as executive shuffle continues<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-17\/#Lilly_nets_best-case_Jardiance_nod_from_FDA\" >Lilly nets best-case Jardiance nod from FDA<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-17\/#AstraZeneca_to_shuffle_off_UK_finance_jobs_as_part_of_11B_cost-cutting_scheme\" >AstraZeneca to shuffle off U.K. finance jobs as part of $1.1B cost-cutting scheme<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-17\/#Roches_Gazyva_aims_to_beat_blockbuster_Rituxan\" >Roche&#8217;s Gazyva aims to beat blockbuster Rituxan<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Glaxo_replaces_ViiV_Healthcare_chief_as_executive_shuffle_continues\"><\/span>Glaxo replaces ViiV Healthcare chief as executive shuffle continues<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The executive exodus at GlaxoSmithKline is continuing\u2014and so is the rise of women to the company\u2019s top ranks. The British pharma giant announced that Dominique Limet, head of HIV unit ViiV Healthcare, would step down at the end of March 2017\u2014the same month the company will bid farewell to longtime CEO Andrew Witty. He\u2019ll be replaced by Deborah Waterhouse, who currently serves as GSK\u2019s SVP of primary care, and VP of U.S. primary care sales Cheryl MacDiarmid will step in for Waterhouse.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Lilly_nets_best-case_Jardiance_nod_from_FDA\"><\/span>Lilly nets best-case Jardiance nod from FDA<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Eli Lilly snagged a new indication for SGLT2 contender Jardiance, meaning it can now directly promote its claims that the drug reduces the risk of cardiovascular death in Type 2 diabetes patients. And with that, predictions are coming that the company should see the \u201cinflection point\u201d in sales that it&#8217;s been waiting for. Regulators handed down the positive decision citing the 38% reduction in cardiovascular death due to the drug Lilly shares with partner Boehringer Ingelheim, posted in its EMPA-REG outcomes trial.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"AstraZeneca_to_shuffle_off_UK_finance_jobs_as_part_of_11B_cost-cutting_scheme\"><\/span>AstraZeneca to shuffle off U.K. finance jobs as part of $1.1B cost-cutting scheme<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Intent on cutting $1.1 billion in annual costs, AstraZeneca will move some finance jobs out of the U.K. to centralized facilities in Malaysia, Costa Rica and Poland as part of a global consolidation plan. The shift of work to \u201cnewly created regional centres\u201d focused on back-office work comes as AstraZeneca faces payer pressure and hits to its overall profitability. The new moves will downsize a finance division in Alderley Park, England, with jobs allocated to the regional centers or to AstraZeneca&#8217;s new headquarters in Cambridge.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Roches_Gazyva_aims_to_beat_blockbuster_Rituxan\"><\/span>Roche&#8217;s Gazyva aims to beat blockbuster Rituxan<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Biosimilars are coming for top-selling Rituxan, and Roche\u2019s drug, Gazyva, aims to take its place. Roche has big plans for its blood cancer medicine. However, Gazyva has a tough task ahead in competing with its own predecessor. At the American Society for Hematology meeting, Novartis and Celltrion rolled out stats on their Rituxan biosims and Roche countered with some more Rituxan-beating Gazyva data, creating an evident atmosphere of rivalry. Gazyva (obinutuzumab) trumped Rituxan in follicular lymphoma patients who hadn\u2019t been treated previously, when tested alongside chemotherapy. This success is even more important to Roche, as Gazyva fell short in diffuse large B-cell lymphoma part\u2014just two months after the follicular lymphoma success. And with Rituxan biosims on the market, Roche will need more time to persuade doctors that Gazyva is better for patients than its predecessor.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glaxo replaces ViiV Healthcare chief as executive shuffle continues The executive exodus at GlaxoSmithKline is continuing\u2014and so is the rise of women to the company\u2019s top ranks. The British pharma giant announced that Dominique Limet, head of HIV unit ViiV Healthcare, would step down at the end of March 2017\u2014the same month the company will [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1534,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,228,269,639,524],"industry":[17225],"therapeutic_areas":[17242,17240,17228],"class_list":["post-1625","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-eli-lilly","tag-glaxosmithkline-plc","tag-pharma-news","tag-roche","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims<\/title>\n<meta name=\"description\" content=\"The executive exodus at GlaxoSmithKline is continuing\u2014and so is the rise of women to the company\u2019s top ranks. The British pharma giant announced that...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-17\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims\" \/>\n<meta property=\"og:description\" content=\"The executive exodus at GlaxoSmithKline is continuing\u2014and so is the rise of women to the company\u2019s top ranks. The British pharma giant announced that...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-17\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-12-06T12:29:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"282\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims","description":"The executive exodus at GlaxoSmithKline is continuing\u2014and so is the rise of women to the company\u2019s top ranks. The British pharma giant announced that...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-17","og_locale":"en_US","og_type":"article","og_title":"Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims","og_description":"The executive exodus at GlaxoSmithKline is continuing\u2014and so is the rise of women to the company\u2019s top ranks. The British pharma giant announced that...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-17","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2016-12-06T12:29:37+00:00","article_modified_time":"2021-07-24T07:26:35+00:00","og_image":[{"width":640,"height":282,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-17","url":"https:\/\/www.delveinsight.com\/blog\/notizia-17","name":"Glaxo replaces ViiV; Lilly nets; AstraZeneca shuffles off; Gazyva aims","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-17#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-17#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","datePublished":"2016-12-06T12:29:37+00:00","dateModified":"2021-07-24T07:26:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The executive exodus at GlaxoSmithKline is continuing\u2014and so is the rise of women to the company\u2019s top ranks. The British pharma giant announced that...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-17"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-17#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura.jpg","width":640,"height":282},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/11\/04164451\/notizie-su-misura-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline PLC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline PLC<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Dec 6, 2016","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Dec 6, 2016 12:29 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1625"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1625\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1534"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1625"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1625"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}